Institution Logo

University of Texas at MD Anderson Cancer Center

Kidney Cancer Program

Primary Address

1515 Holcombe Blvd
Houston, TX, 77030

Satellite Locations

League City

2280 Gulf Freeway South League City, TX 77573

West Houston

13900 Katy Freeway Houston, TX 77079

The Woodlands

100 Fellowship Drive Conroe, TX 77384

Sugarland

1327 Lake Pointe Parkway Sugarland, TX 77478

Key Contacts

Medical Oncology Lead:
Dr. Matthew Campbell MD, MS – Associate Professor, Associate Medical Director
Medical Oncology:
Dr. Nizar Tannir MD, FACP – Professor
Medical Oncology:
Dr. Pavlos Msaouel MD, PhD – Associate Professor
Medical Oncology:
Dr. Eric Jonasch – Professor
Medical Oncology:
Dr. Amado Zurita – Professor
Medical Oncology:
Dr. Amishi Shah – Associate Professor
Medical Oncology:
Dr. Jianjun Gao MD, PhD – Professor
Medical Oncology:
Dr. Sangeeta Goswami MD, PhD – Associate Professor
Medical Oncology:
Dr. Andrew Hahn – Assistant Professor
Medical Oncology:
Dr. Andrew Johns – Assistant Professor
Urologic Surgery Lead:
Jose Karam FACS – Professor
Urology:
Dr. Surena Matin – Professor
Urology:
Dr. Brittney Cotta – Assistant Professor
Radiation Oncology Lead:
Dr. Chad Tang – Associate Professor
Radiation Oncology:
Dr. Quynh Nguyen – Professor
Patient Navigator & Appointments:
Call (877) 632-6789
Clinical Trials Contact:
[email protected]
(877) 632-6789

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

High

Clear Cell Kidney Cancer Diagnosis Volume

Very High

Non–Clear Cell Kidney Cancer Diagnosis Volume

Very High

Clinical Trial Participation Volume

Very High

Radiation & Ablation Procedure Volume

High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Integrated Multidisciplinary Clinic Integrative Oncology Molecular Testing Oncology Urgent Care Clinic Patient Case Discussions / Tumor Boards Precision Medicine Supportive Care / Pain Clinics Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pediatric (diagnosed under age 18) Pregnancy Solitary Kidney Young Adult (age 18-50)

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research Member of Kidney Cancer Consortium NCI Designated Cancer Center

Consortium Member

Yes

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

Internal & Texas Medical Center Partners
National & International Research Networking
Cross-Institution Research Program
Clinical & Treatment Network Extensions

Patient Resources & Support Services

Art Therapy Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Lymphedema Therapy Music Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Pastoral / Spiritual Care Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Remote Monitoring Tools Social Workers / Counselors Transportation Service Wellness Center

Insurance Carriers

Accepted

  • Traditional Medicare (Part A andB)
  • Traditional Texas Medicaid
  • Aetna- HMO- PPO- POS - Select Choice
  • Blue Cross Blue Shield of Texas (BCBS-TX)
  • Cigna- PPO- HMO- Open Access
  • Some Medicare Advantage/ Managed-care plans
  • Self-Pay and Financial Assistance Program

Not Accepted

  • ACA Marketplace/ Individual Plans
  • Blue Cross Blue Shield- Blue Advantage HMO /Blue Advantage Plus HMO / MyBlueHealth / Blue Premier/ Blue Premier Access/ Blue High-Performance Network (HPN)
  • BCBS-TX Medicare Advantage Plans
  • BCBS-TX Medicaid Managed- Care plans
  • Individual-market Plans from Aetna / Cigna / and United Healthcare

Open Clinical Trials

Bone Renal Cell Carcinoma Study

Front line study of metastatic clear cell renal cell carcinoma with bone metastases, treatment with nivolumab plus cabozantinib.

Ivory

Ivonescimab in metastatic clear cell renal cell carcinoma

TANKeR 70

CAR NK targeting CD70 for clear cell renal cell carcinoma

Starlite Geruntuximab

177Lu geruntuxuimab plus cabozantinib plus nivolumab study of metastatic clear cell renal cell carcinoma

RCC Brain mets

nivolumab plus ipilimumab plus cabozantinib for de novo brain metastases

FORTUNE

nivolumab plus tivozanib in patients with metastatic non-clear cell renal cell carcinoma

10466 NCI

atezolizumab plus bevacizumab plus erlotinib in papillary or HLRCC

ASTROS

SBRT+/-pembrolizumab oligometastatic RCC

EXTEND OP

SBRT or change of therapy for oligoprogressive RCC

RMC MUC16 CD3 Bispecific T cell

cellular therapy for renal medullary carcinoma